mita, thanks for your posts and ideas. What is your valuation...

mita, thanks for your posts and ideas. What is your valuation based upon current, say 14% market share of Axiron, please?

I think there's some positives here, with Axiron having a 10% price increase recently- it means that there canbe 10% less sales, and it works out neutral. The new markets are potentially lucrative, and ACR seems to have few barriers to open up new markets- they do it quickly! Surely this must make up some level of fewer sales in the US. Also, the royalty payments to Monash end in 2017- it's a long time away, but it will add to ACR's bottom line.

It is a battle here between the thoughts of Macquarie (and UBS, who have just made a share borrowing agreement), and Orbis/Allan Gray and bell Potter. One would think with added pressure for ACR to move on with developments related to pipeline products, and perhaps some pressure from major shareholders re cutting corporate costs (although these remain at $5m per annum, which is not too bad), that ACR can pull through this funk. The PE/r will be quite low if this keeps falling. Value funds are sure to enter.